Showing results (51-60 of 157) with videos related to
Sort By:
Pageof 16
Lung Cancer (Amsterdam, Netherlands)|October 19, 2025
Efficacy and safety of brigatinib after alectinib in patients with ALK-positive NSCLC: Integrated analysis of the ALTA-2 and J-ALTA studiesTony Mok, Makoto Nishio, Tatsuya Yoshida, et al.Medical Oncology (Northwood, London, England)|August 20, 2005
Liver resection after irinotecan, 5-fluorouracil, and folinic acid for patients with unresectable colorectal liver metastases: a multicenter phase II study by the Cancer Therapeutic Research GroupWing M Ho, B Ma, Tony Mok, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2016
Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLungDavid R Spigel, Martin J Edelman, Kenneth O'Byrne, et al.Clinical Lung Cancer|February 4, 2014
Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic OncologyCesare Gridelli, Filippo de Marinis, Federico Cappuzzo, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 4, 2016
First-Line Pemetrexed plus Cisplatin followed by Gefitinib Maintenance Therapy versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer: Final Overall Survival Results from a Randomized Phase 3 StudyJames Chih-Hsin Yang, Vichien Srimuninnimit, Myung-Ju Ahn, et al.Cancer Discovery|May 8, 2024
D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical ActivitiesJing Zhang, Sun Min Lim, Mi Ra Yu, et al.Investigational New Drugs|September 14, 2007
A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cellsBrigette Ma, Boon Cher Goh, Eng Huat Tan, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 17, 2016
Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR MutationsBarbara Klughammer, Wolfram Brugger, Federico Cappuzzo, et al.Radiology|October 16, 2013
Unresectable hepatocellular carcinoma: randomized controlled trial of transarterial ethanol ablation versus transcatheter arterial chemoembolizationSimon Chun Ho Yu, Joyce Wai Yi Hui, Edwin Pun Hui, et al.Future Oncology (London, England)|July 30, 2019
Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancerRachel Woodford, Yanni Loh, Joanna Lee, et al.Pageof 16